Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue-engineered bone from BMP-2-transduced stem cells derived from human fat.

Jason L Dragoo1, Jay R Lieberman, Richard S Lee

  • 1Department of Orthopedic Surgery, Laboratory for Regenerative Bioengineering and Repair, University of California, Los Angeles, California, USA.

Plastic and Reconstructive Surgery
|April 30, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination ex vivo regional gene therapy with sonic hedgehog and bone morphogenetic protein-2 does not enhance bone healing in critical size defects.

Connective tissue research·2026
Same author

Orthobiologics at a Crossroads: From Biological Promise to Evidence-Based Orthopaedic Practice.

The Journal of bone and joint surgery. American volume·2026
Same author

Reassessing Total Joint Arthroplasty Case Volumes in The United States: Accounting for Ultra-Low-Volume Surgeons.

The Journal of arthroplasty·2026
Same author

Neutrophil-Lymphocyte Ratio Trajectories Predict Mortality and Medical Complications in Hip Fracture Patients Undergoing Hemiarthroplasty.

The Journal of arthroplasty·2026
Same author

Transfusions Are Associated With an Elevated Risk of Venous Thromboembolism and Periprosthetic Joint Infection Following Revision Total Knee Arthroplasty.

The Journal of arthroplasty·2026
Same author

Factor XI and XIa Inhibitors for Venous Thromboembolism Prophylaxis After Total Knee Arthroplasty: A Review From Mechanism to Phase III Trials.

The Journal of arthroplasty·2026

Processed lipoaspirate cells from adipose tissue can be genetically modified with bone morphogenetic protein-2 (BMP-2) to effectively induce bone formation in vivo. This discovery holds promise for bone tissue engineering and regenerative medicine applications.

Area of Science:

  • Biomaterials Science
  • Tissue Engineering
  • Cell Biology

Background:

  • Processed lipoaspirate cells (PLAPCs) are progenitor cells from human liposuction aspirates with demonstrated in vitro osteogenic potential.
  • Previous research has established the capacity of PLAPCs to differentiate into multiple mesenchymal lineages.

Purpose of the Study:

  • To evaluate the in vivo bone induction capacity of PLAPCs genetically modified with bone morphogenetic protein-2 (BMP-2).
  • To assess the efficacy of BMP-2-transduced PLAPCs using adipose tissue from diverse anatomical locations.

Main Methods:

  • PLAPCs were isolated from abdominal, buttock, and infrapatellar fat pad adipose tissue.
  • Cells were transduced with an adenovirus carrying the BMP-2 gene (adBMP-2) or left untransfected as controls.

Related Experiment Videos

  • Transfected cells were seeded onto collagen I matrices and implanted into immunodeficient mice for 6 weeks.
  • Bone formation was analyzed using radiography, densitometry, and histological staining.

    • Main Results:

    • BMP-2-transduced PLAPC constructs consistently generated abundant radiographic and histologic bone.
    • The induced bone exhibited adequate mineralization and early marrow cavity formation.
    • No significant difference in bone production was observed between adipose tissue from the knee and abdomen/buttock harvest sites.

    Conclusions:

    • Multipotential PLAPCs can be successfully harvested from various adipose tissue sources.
    • Gene transduction with BMP-2 enables PLAPCs to induce significant in vivo bone formation.
    • These findings suggest clinical utility of PLAPCs for bone tissue engineering, either as osteoprogenitor cells or BMP-2 delivery vehicles.